We are now wel and truly out of the woods with Relenza the CDC is now going to announce that Relenza is now the preferred treatment for the H1N1 ( swine flu ) and for the seasonal Flu due to the resistance regarding Tamiflu.
I have said before Biota is a no brainer and a multi bagger in the making from here.
How more days we have to wait before the shareprice is going to fly????
Not that many more imho as the capper with its 2 million of so shares on the sale side will have to capitulate once the market wakes and fresh buying pushes up the price.
Here is the article enjoy , especially for the long term holders you will all get your money back and probably much more then you have bargained for.....
Please do your own research because as I have said before I am heavily invested in BTA and have a biased opinion...
Which Anti-Viral Drugs Have Governments World-Wide Stock-piled? Cheree Cleghorn | July 3, 2009 Yesterday’s report in Medpage Today that the CDC will advise that the drug Relenza is the “preferred” treatment for seasonal and the H1N1 variation known as swine flu, prompts this question: What drugs have governments world-wide been stock-piling to treat patients in the 2009 pandemic?
This report is not a surprise. News of Tamiflu resistance has been mentioned since spring although not prominently. Researchers have been aware that drug resistance could be a problem. What may be surprising to planners is the overwhelming evidence that only one drug appears to be effective rather than being more effective. They do not make those kinds of statements in public or not, at least, in the middle of the situation.
To date, the cases reported have tended to be mild but the history of pandemics suggests that the fall could bring a second round of cases, more acute ones. If history repeats itself, is the world ready for an acute phase with the right antiviral in the right amounts?
The Relenza recommendation comes from the CDC’s Advisory Committee on Immunization Practices.
The most recent report located on what governments have done is dated April 27, 2009.
The second quarter of the fiscal year ended June 30, so there should be additional reports on the volume of sales of Relenza to governments shortly.
Bloomberg News
“April 27 (Bloomberg) — GlaxoSmithKline Plc’s flu drug Relenza beat Roche Holding AG’s Tamiflu in sales to governments for the first time last quarter, a sign authorities are seeking a broader range of medicines to protect against a pandemic.
“Government orders of Relenza were 20 percent higher than those for Tamiflu in the first quarter, according to data from both companies released before the current swine flu outbreak.
“Demand for Relenza was stoked by reports of widespread resistance of H1N1, a common seasonal flu virus, to Tamiflu. The U.K. and Japan increased orders for the drug to prepare for a possible influenza pandemic on concern Tamiflu-evading seasonal flu could exchange genes with a pandemic strain, making that pill a weaker weapon against a global contagion. Almost all H1N1 samples tested last winter were resistant to Tamiflu, the World Health Organization said.
“Governments are balancing their stockpiles” by including more Relenza, said Stephen Rea, a spokesman for London-based Glaxo, in an April 24 phone interview. “Our expectation would be that other governments would follow suit. Our view would be the U.S. government would also be persuaded.”
Source: Bloomberg News, April 27, 2009
Topics: Top Stories
BTA Price at posting:
$1.30 Sentiment: LT Buy Disclosure: Held